Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.

The oncologist - 1 Jan 2003

Ross Jeffrey S, Fletcher Jonathan A, Linette Gerald P, Stec James, Clark Edward, Ayers Mark, Symmans W Fraser, Pusztai Lajos, Bloom Kenneth J

Abstract excerpt

The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. In this review, the association of HER-2/neu gene and protein abnormalities with prognosis and response to therapy with trastuzumab and to other therapies in br...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Distribution
Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms, Male

Share to Combined Modality Therapy

Share to Genes, erbB-2

Share to Survival Analysis

Share to Trastuzumab

Source

Identifiers

PMID: 12897328
DOI: 10.1634/theoncologist.8-4-307

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-12897328-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.PMID 12897328Read ↗

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineSemantic proximity Read ↗

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerSemantic proximity Read ↗

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.Semantic proximity Read ↗

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic ConsiderationsSemantic proximity Read ↗

“Omics” of HER2-Positive Breast CancerSemantic proximity Read ↗

HER-2/neu diagnostics in breast cancer.Semantic proximity Read ↗

Diagnostic utility of oncogenes and their products in human cancer.Semantic proximity Read ↗

Breast cancer biomarker measurements and standardsSemantic proximity Read ↗

Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing.Semantic proximity Read ↗

HER-2/neu Gene Copy Number Quantified by Real-Time PCR: Comparison of Gene Amplification, Heterozygosity, and Immunohistochemical Status in Breast Cancer TissueSemantic proximity Read ↗

Comparison of HER-2/ neu Oncogene Amplification Detected by Fluorescence In Situ Hybridization in Lobular and Ductal Breast CancerSemantic proximity Read ↗

Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.